Sign In
Buy SRPT
$18.95
-1.57 (-7.65%)
At Close: Jul 10, 2026
2 Beaten-Down Stocks That Still Aren't Worth Buying
04:30pm, Saturday, 11'th Jul 2026
Recursion Pharmaceuticals has yet to prove that its approach to developing medicines is superior. Sarepta Therapeutics will struggle to shake off safety concerns about its most important therapy.
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
12:04pm, Friday, 10'th Jul 2026
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:25pm, Tuesday, 30'th Jun 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously app
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs
12:44pm, Tuesday, 30'th Jun 2026
The U.S. Food and Drug Administration (FDA) accepted on Tuesday Sarepta Therapeutics Inc.'s (NASDAQ:SRPT) supplemental New Drug Applications seeking to convert the accelerated approvals of AMONDYS 45
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
09:00am, Tuesday, 30'th Jun 2026
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administratio
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
08:30am, Tuesday, 30'th Jun 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA
SRPT or PRTA: Which Is the Better Value Stock Right Now?
12:41pm, Wednesday, 24'th Jun 2026
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Sarepta Therapeutics (SRPT) and Prothena (PRTA). But which of these two stocks is more attractive to value inv
Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
02:48pm, Monday, 08'th Jun 2026
Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy
01:01pm, Monday, 08'th Jun 2026
Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SRPT vs. ARGX: Which Stock Is the Better Value Option?
12:41pm, Monday, 08'th Jun 2026
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Sarepta Therapeutics (SRPT) or argenex SE (ARGX). But which of these two companies is the bes
Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?
12:35pm, Friday, 05'th Jun 2026
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript
11:41am, Thursday, 04'th Jun 2026
Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
04:30pm, Monday, 01'st Jun 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the
My Top 3 Biotech Stocks for May 2026
11:15am, Wednesday, 20'th May 2026
As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd.
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
04:30pm, Wednesday, 13'th May 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi
